ProNAi Therapeutics Inc. (NASDAQ:DNAI)’s share price was up 3.6% during trading on Wednesday . The stock traded as high as $2.03 and last traded at $2.01, with a volume of 383,128 shares traded. The stock had previously closed at $1.94.

Several equities research analysts have recently issued reports on DNAI shares. Wedbush reaffirmed an “outperform” rating and issued a $36.00 price target on shares of ProNAi Therapeutics in a research report on Friday, May 27th. Jefferies Group downgraded ProNAi Therapeutics from a “buy” rating to a “hold” rating and lowered their price target for the company from $22.00 to $4.50 in a research report on Monday, June 6th. SunTrust Banks Inc. downgraded ProNAi Therapeutics from a “buy” rating to a “neutral” rating and lowered their price target for the company from $25.00 to $4.00 in a research report on Monday, June 6th. Finally, Zacks Investment Research raised ProNAi Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 price target on the stock in a research report on Tuesday, March 8th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $17.35.

The stock’s 50-day moving average is $3.41 and its 200 day moving average is $6.72. The stock’s market capitalization is $62.16 million.

ProNAi Therapeutics (NASDAQ:DNAI) last released its quarterly earnings results on Tuesday, May 10th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.07. On average, equities research analysts expect that ProNAi Therapeutics Inc. will post ($1.46) earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in ProNAi Therapeutics stock. Jennison Associates acquired a new stake in ProNAi Therapeutics Inc. (NASDAQ:DNAI) during the third quarter, Holdings Channel reports. The fund acquired 150,381 shares of the company’s stock, valued at approximately $3,086,000. Jennison Associates owned 0.50% of ProNAi Therapeutics at the end of the most recent reporting period.

ProNAi Therapeutics, Inc is a clinical-stage oncology company. The Company is engaged in business of researching, developing and commercializing therapies for the treatment of patients with cancer and hematological diseases based on its deoxyribonucleic acid interference (DNAi) technology platform. Its lead product candidate includes PNT2258, which targets cancers that overexpress B-cell lymphoma 2 (BCL2), an oncogene known to be dysregulated in various types of cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.